The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease

Bibliography

• Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharm 2010;66:119-25
   PubMed Web of Science ®Google Scholar
• Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol 2012;25:433-47
   PubMed Web of Science ®Google Scholar
• Gardian G, Vecsei L. Medical treatment of Parkinson's disease: today and the future. Int J Clin Pharmacol Ther 2010;48:633-42
   PubMed Web of Science ®Google Scholar
• Sage JI, Mark MH. Basic mechanisms of motor fluctuations. Neurology 1994;44:S10-14
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677-92
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with ‘Madopar’ and L-deprenil in Parkinson's disease. A long-term study. Lancet 1977;1:439-43
   PubMed Web of Science ®Google Scholar
• Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408
   PubMedGoogle Scholar
• Tatton WG, Ju WY, Holland DP, (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-5
   PubMed Web of Science ®Google Scholar
• Wadia JS, Chalmers-Redman RM, Ju WJ, Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998;18:932-47
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 1999;111:189-200
   PubMed Web of Science ®Google Scholar
• Magyar K, Szende B, Lengyel J, The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm Suppl 1998;52:109-23
   PubMedGoogle Scholar
• Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther 2011;17:345-67
   PubMed Web of Science ®Google Scholar
• Magyar K, Pálfi M, Tábi T, Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004;11:2017-31
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33:91-102
   PubMed Web of Science ®Google Scholar
• Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dipos 1997;25:657-62
   PubMed Web of Science ®Google Scholar
• Katagi M, Tatsuno M, Miki A, Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 2001;759:125-33
   PubMed Web of Science ®Google Scholar
• Magyar K, Tóthfalusi L. Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 1984;36:373-84
   PubMedGoogle Scholar
• Yoshida T, Yamada Y, Yamamoto T, Kuroiwa Y. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency. Xenobiotica 1986;16:129-36
   PubMed Web of Science ®Google Scholar
• Szökő É, Magyar K. Enantiomer identification of major metabolites of (-)-deprenyl in rat urine by capillary electrophoresis. Int J Pharm Adv 1996;1:320-8
   Google Scholar
• Heinonen EH, Myllyla V, Sotaniemi K, Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand Suppl 1989;126:93-9
   PubMedGoogle Scholar
• Szökő É, Tábi T, Halász AS, Chiral characterization and quantification of deprenyl-N-oxide and other deprenyl metabolites in rat urine by capillary electrophoresis. Chromatographia 2004;60:S245-51
   Web of Science ®Google Scholar
• Tábi T, Magyar K, Szökő É. Chiral characterization of deprenyl-N-oxide and other deprenyl metabolites by capillary electrophoresis using a dual cyclodextrin system in rat urine. Electrophoresis 2003;24:2665-73
   PubMed Web of Science ®Google Scholar
• Lévai F, Fejer E, Szeleczky G, In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog. Eur J Drug Metab Pharmacokinet 2004;29:169-78
   PubMed Web of Science ®Google Scholar
• Szökő É, Tábi T, Borbás T, Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis 2004;25:2866-75
   PubMed Web of Science ®Google Scholar
• Haberle D, Szökő É, Magyar K. The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 2002;9:47-51
   PubMed Web of Science ®Google Scholar
• Schachter M, Marsden CD, Parkes JD, Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980;43:1016-21
   PubMed Web of Science ®Google Scholar
• Szökő É, Kalász H, Magyar K. Biotransformation of deprenyl enantiomers. Eur J Drug Metab Pharmacokinet 1999;24:315-19
   PubMed Web of Science ®Google Scholar
• Harsing LG Jr, Magyar K, Tekes K, Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 1979;31:297-307
   PubMedGoogle Scholar
• Magyar K, Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004;25:233-42
   PubMed Web of Science ®Google Scholar
• Frampton JE, Plosker GL. Selegiline transdermal system: in the treatment of major depressive disorder. Drugs 2007;67:257-65; discussion 66-7
   PubMed Web of Science ®Google Scholar
• Goodnick PJ. Seligiline transdermal system in depression. Expert Opin Pharmacother 2007;8:59-64
   PubMed Web of Science ®Google Scholar
• Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007;3:527-37
   PubMedGoogle Scholar
• Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998;50:375-82
   PubMed Web of Science ®Google Scholar
• Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992;81:1-10
   PubMed Web of Science ®Google Scholar
• Clarke A, Brewer F, Johnson ES, A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1241-55
   PubMed Web of Science ®Google Scholar
• Barrett JS, Rohatagi S, DeWitt KE, The effect of dosing regimen and food on the bioavailability of the extensively metabolized, highly variable drug Eldepryl® (selegiline hydrochloride). Am J Ther 1996;3:298-313
   PubMedGoogle Scholar
• Waters CH, Sethi KD, Hauser RA, Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-32
   PubMed Web of Science ®Google Scholar
• Ondo WG, Sethi KD, Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Clin Neuropharmacol 2007;30:295-300
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007;27:174S-85S
   PubMed Web of Science ®Google Scholar
• Lew MF, Pahwa R, Leehey M, Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off' episodes in patients with Parkinson's disease. Curr Med Res Opin 2007;23:741-50
   PubMed Web of Science ®Google Scholar
• Lyons KE, Friedman JH, Hermanowicz N, Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010;33:5-10
   PubMed Web of Science ®Google Scholar
• Clarke A, Johnson ES, Mallard N, A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1257-71
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hunter C, Isaacson SH, Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord 2011;17:117-18
   PubMed Web of Science ®Google Scholar
• Shoulson I, Oakes D, Fahn S, Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-12
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8
   PubMed Web of Science ®Google Scholar
• Abu-Raya S, Tabakman R, Blaugrund E, Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002;434:109-16
   PubMed Web of Science ®Google Scholar